Overview

Vosevi is a once-daily, single-tablet regimen combining sofosbuvir, velpatasvir, and voxilaprevir for adults with chronic hepatitis C virus infection who have prior direct-acting antiviral (DAA) experience. Its role is distinct from first-line therapy: it is positioned for retreatment where earlier regimens left resistance-associated substitutions that limit alternative options. The retreatment window is narrow because not every pangenotypic regimen covers patients who already failed an NS5A inhibitor, so understanding where Vosevi fits protects both access and outcomes.

The Three Mechanisms of Action

Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B RNA-dependent RNA polymerase. Velpatasvir inhibits NS5A, a viral phosphoprotein required for replication and assembly. Voxilaprevir is a third-generation NS3/4A protease inhibitor. By hitting three separate steps in the viral lifecycle, the combination reduces the chance that a single class of resistance substitution will compromise the whole regimen. Each component is orally bioavailable in the fixed-dose tablet, which supports a defined treatment course under labeling.

Resistance-Associated Substitutions in Prior Therapy

Patients who failed an NS5A inhibitor may carry substitutions at positions such as 24, 28, 30, 31, 32, 58, 92, and 93 of NS5A, while NS3/4A experience can leave protease substitutions. Sofosbuvir's barrier is comparatively high, with the NS5B S282T substitution being rare. Vosevi was developed so that voxilaprevir retains activity against many NS5A and NS3 substitutions that limited earlier protease inhibitors, making it a retreatment option for suitable DAA-experienced patients.

When Baseline RAS Testing Matters

For individuals with prior NS5A inhibitor exposure, baseline resistance testing can inform the likelihood of sustained virologic response and supports regimen selection per specialist guidance. Genotype coverage spans HCV genotypes 1 through 6. Specialists weigh the prior regimen class because NS5A inhibitor exposure carries the strongest resistance signal among the three components, and retreatment eligibility depends on the precise prior treatment history.

FAQ

Q: Is Vosevi a first-line hepatitis C treatment? A: No. It is indicated for adults with prior DAA experience, not treatment-naive patients. First-line care typically uses other pangenotypic regimens.

Q: Why does voxilaprevir matter for resistance? A: Voxilaprevir is a third-generation NS3/4A protease inhibitor that remains active against many substitutions left by earlier NS5A or protease inhibitors, supporting retreatment.

Q: Do all retreated patients need RAS testing? A: Testing is most informative after NS5A inhibitor failure. Specialists use the result together with genotype and treatment history to confirm suitability under the labeling.